{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"80","value":"67"}]}],"title":"Overall"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19","upperLimit":"44","value":"31"}]}],"title":"Complete"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"Response was assessed per standard criteria (Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria fornon-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253.)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.","id":"OG000","title":"Treatment"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3-4 weeks after completion of study treatment","title":"Overall and Complete Response Rates","type":"SECONDARY","unitOfMeasure":"percentage of participants"}